Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Otsuka’s PDE4 Inhibitor Difamilast Delivers Positive Data for Atopic Dermatitis in Japan PIII
Otsuka Pharmaceutical’s phosphodiesterase 4 (PDE4) inhibitor difamilast (OPA-15406) has demonstrated positive top-line results in two Japan PIII clinical studies in patients with atopic dermatitis, which enrolled adult and pediatric patients, respectively, the company said on March 26. The two PIII…
To read the full story
Related Article
- Otsuka Files Japan NDA for Atopic Dermatitis Drug Difamilast
September 29, 2020
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





